Studies a COPD follow-up tool after flare-ups needing emergency care
Tests an AI-based tool that helps arrange specialist follow-up for people with COPD flare-ups.
Plain-language title generated from the registry record
Registry title: COPD Exacerbation Follow Up
Key facts
- Where
- Cherry Hill, Falls Church, Milwaukee, Park Ridge, and Philadelphia, United StatesSee the 5 sites
Where in United States
- Cooper University Health CareCherry Hill, United StatesTaking people
- Inova Fairfax HospitalFalls Church, United StatesNot yet recruiting
- Aurora St. Luke's Medical CenterMilwaukee, United StatesNot yet recruiting
- Advocate Lutheran General HospitalPark Ridge, United StatesTaking people
- Thomas Jefferson UniversityPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Viz.ai, Inc.
- Trial code
- NCT07118306
- Record updated
- 2 September 2026
- Original description
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.Read full original descriptionShow less
A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
Inclusion: Patients aged 40 years or older at the time of arrival to the emergency department; Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation; A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics; A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death; Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.
Exclusion: Patients who have received a lung transplant; Patients with advanced cancer; Patients on bronchodilator inhaler monotherapy; Patients leaving against medical advice or expiring during hospitalization; Patients with tracheostomy; Discharge to hospice care; Transfer to another hospital.